1. Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves’ disease and predictors of responsiveness to methimazole
- Author
-
Yun Shi, TianT. Li, Tao Yang, SunQ. Liu, XuQ. zheng, Yun Cai, Yu Fu, DouD. Chen, KunY. Liu, and ChengC Zhao
- Subjects
Adult ,Male ,medicine.medical_specialty ,Graves' disease ,Clinical Biochemistry ,Trab ,Thyroid Function Tests ,Gastroenterology ,Autoimmune thyroiditis ,Young Adult ,Internal medicine ,medicine ,Humans ,Aged ,Immunoassay ,Methimazole ,Receiver operating characteristic ,medicine.diagnostic_test ,biology ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Graves Disease ,Graves Ophthalmopathy ,Titer ,Treatment Outcome ,Case-Control Studies ,biology.protein ,Thyroid Stimulating Immunoglobulin ,Female ,Antibody ,business ,Immunoglobulins, Thyroid-Stimulating - Abstract
Background As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves' disease (GD), measuring TSI titers is becoming increasingly important for GD diagnosis. This study evaluated the diagnostic accuracy of a new fully automated TSI immunoassay (Immulite™ TSI assay) in GD patients and compared it to the third generation thyroid-stimulating hormone receptor antibody (TRAb) electrochemiluminescence assay (Elecsys Anti-TSHR assay). Additionally, clinical characteristics associated with responsiveness to methimazole in patients with newly diagnosed GD were preliminarily explored. Methods This study involved 324 subjects, comprising patients with untreated GD (GD-UT), Graves’ ophthalmopathy (GO) patients, GD patients who had been treated for > 12 months (GD-T), autoimmune thyroiditis (AIT) patients, and healthy subjects (HS). The Immulite™ TSI and Elecsys Anti-TSHR assay were performed on all samples. According to their responsiveness to methimazole, the GD-UT patients were divided into rapid and slow responder groups, and their clinical characteristics were compared. Results A receiver operating characteristic (ROC) curve analysis of GD-UT patients showed that the optimal TSI cut-off value was 0.57 IU/L. Logistic regression revealed that age and initial FT4 and TSI levels in the middle-dose methimazole group were related to a rapid response, while the initial FT4 level, but not TSI, in the high-dose group was also associated with a rapid response. Conclusions The clinical diagnostic performance of the Immulite™ TSI assay for diagnosing GD was comparable to that of the Elecsys Anti-TSHR assay. The initial FT4 and TSI levels can be used as predictors of the responsiveness to methimazole in patients with newly diagnosed GD.
- Published
- 2021